Why MGO survives gamma irradiation — the chemistry of a sterile honey dressing

Almost every objection to medical-grade honey starts in the same place: surely the sterilisation kills the activity. It is a sensible question. Heat-pasteurise a jar of any honey and a meaningful fraction of its peroxide-driven antibacterial action goes with it. The enzymes that generate hydrogen peroxide (glucose oxidase and bee defensin-1) are protein. Protein denatures.

Manuka does not depend on those enzymes. Its signature compound is methylglyoxal — a non-enzymatic, non-peroxide, non-peptide molecule. To understand why a 25-kilogray gamma dose leaves it standing, it helps to look at what methylglyoxal actually is.

A small, stubborn molecule

Methylglyoxal (CH₃COCHO) is a 72-dalton α-oxoaldehyde. For context, the bee defensin-1 peptide active in non-Manuka medical honeys is roughly 4,500 daltons — sixty times larger and folded into a structure that ionising radiation can readily disrupt. Small, achiral molecules without secondary or tertiary structure have very few bonds to break, and the bonds they do have (C–C, C=O) are among the most radiation-stable in organic chemistry.¹

Methylglyoxal in Manuka honey is also not free in solution at any meaningful fraction. It exists in equilibrium with its hydrate and with reversible adducts to glucose, fructose and amino acids. The equilibrium acts as a reservoir: even when a small population of free MGO is consumed by a reaction, the adducts release more. Mavric and colleagues quantified this directly when they first isolated MGO as the dominant antibacterial in 2008.²

What gamma actually does

A validated gamma sterilisation cycle for medical honey is typically 25 kGy of cobalt-60 radiation, delivered to a load whose pre-sterilisation bioburden has already been characterised under ISO 13485 and dose-set per ISO 11137.³ The dose is calibrated to deliver a sterility assurance level of 10⁻⁶ — a one-in-a-million probability of a viable organism in the unit. It is delivered through the primary packaging, in a single pass, at ambient temperature.

Gamma photons damage cells in two ways: by direct ionisation of DNA, and indirectly via radiolytic water radicals. DNA is a long, large, fragile target — a few hundred breaks at the right places kills any bacterium or spore present. A small organic molecule like methylglyoxal is the opposite kind of target: too small to be statistically likely to absorb a damaging hit, and chemically simple enough that the radiolytic radicals have little to work with. The same logic explains why glucose, fructose and the bulk sugars of honey emerge essentially unchanged.

The empirical answer

Theory aside, this has been measured. Molan and Allen reported in 1996 that gamma irradiation at 25 kGy produced no detectable loss of antibacterial activity in Manuka honey, in contrast to a meaningful drop in non-Manuka honeys whose activity was peroxide-derived.⁴ Industry batch-release data for modern medical-grade Manuka dressings show MGO retention of ≥ 95% post-sterilisation across normal cycle variation.

What it means for a dressing

The practical consequence is that a CE- or FDA-cleared Manuka dressing can be put on a wound with the same confidence as any sterile single-use device. The activity profile that mattered when the honey left the hive — the MGO/DHA ratio, the water activity, the pH — is the activity profile at the bedside.